Shares of Charles River Laboratories International Inc. CRL advanced 2.38% to $170.59 Wednesday, on what proved to be an ...

This was the stock's second consecutive day of losses.

Charles Schwab Investment Management Inc. boosted its position in shares of Charles River Laboratories International, Inc.

Bell Asset Management, an investment management company, released its Q4 2024 “Bell Global Equities Fund” investor letter. A ...

Smartleaf Asset Management LLC raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – ...

Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, ...

Charles River Labs (CRL) stock and LabCorp (LH) stock were upgraded and Quest Diagnostics (DGX) stock was downgraded at Citi.

Charles River Laboratories is navigating a challenging biopharmaceutical demand environment with strategic cost-saving initiatives and a focus on stabilizing revenue trends. While pricing ...

To properly understand Charles River Laboratories International's profit results, we need to consider the US$324m expense attributed to unusual items. It's never great to see unusual items costing the ...

FibroBiologics (FBLG) and Charles River Laboratories (CRL) announced the completion of FibroBiologics’ proprietary master cell bank that will ...

East Lothian Uncaged is a group of eccentric and devoted campaigners who protest outside Charles River - a massive animal ...

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 27 th Annual Global Healthcare Conference on Wednesday, March 12 th, at 9:30 a.m. ET.